Full text
PDF
. 1948 Mar;27(2):278–282. doi: 10.1172/JCI101944
SENSITIVITY OF THE TUBERCLE BACILLUS TO STREPTOMYCIN BEFORE AND DURING SPECIFIC THERAPY 1,2,3
Joseph F Sadusk Jr
1,2, William E Swift Jr
1,2, Eleanora Falco
1,2, John Vadney
1,2
Joseph F Sadusk Jr
1Department of Internal Medicine, Yale University School of Medicine, New Haven
2Laurel Heights Sanatorium, Shelton, Conn.
Find articles by Joseph F Sadusk Jr
William E Swift Jr
1Department of Internal Medicine, Yale University School of Medicine, New Haven
2Laurel Heights Sanatorium, Shelton, Conn.
Find articles by William E Swift Jr
Eleanora Falco
1Department of Internal Medicine, Yale University School of Medicine, New Haven
2Laurel Heights Sanatorium, Shelton, Conn.
Find articles by Eleanora Falco
John Vadney
1Department of Internal Medicine, Yale University School of Medicine, New Haven
2Laurel Heights Sanatorium, Shelton, Conn.
Find articles by John Vadney
1Department of Internal Medicine, Yale University School of Medicine, New Haven
2Laurel Heights Sanatorium, Shelton, Conn.
1
Presented in part at a symposium on streptomycin therapy of pulmonary tuberculosis before the Yale Medical Society, New Haven, May 14, 1947; and at the Eastern Sectional Meeting of the American Federation for Clinical Research, New York City, December 12, 1947.
2
This study was aided by a grant from the Fluid Research Fund of the Yale University School of Medicine.
3
This study is part of the Streptomycin-Tuberculosis Research Project of the American Trudeau Society, Medical Section, National Tuberculosis Association. The drug was generously donated to the Society by the following: Abbott Laboratories, Eli Lilly & Co., Merck & Co., Inc., Charles Pfizer & Co., Inc., E. R. Squibb & Sons, and the Upjohn Co. Collateral clinical observations were made at the Laurel Heights Sanatorium by Dr. Kirby S. Howlett, Jr., and Dr. John B. O'Connor to whom the authors are indebted for generous advice and assistance with the reported study.
PMCID: PMC439502 PMID: 16695552